Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management

References

• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–326. doi: 10.1016/j.cell.2018.09.035 PMID: 30290139; PMCID: PMC6538253.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–249. doi: 10.1146/annurev-pathol-042020-042741 PMID: 33197221.
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415–1422. doi: 10.1038/s41590-023-01569-z PMID: 37488429.
   PubMedGoogle Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. doi: 10.1093/annonc/mdx286 PMID: 28945858.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. doi: 10.1016/S0140-6736(21)01206-X PMID: 34509219.
   PubMed Web of Science ®Google Scholar
• Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford). 2019;58(Suppl 7):vii68–vii74. doi: 10.1093/rheumatology/kez295 PMID: 31816082; PMCID: PMC6900916.
   PubMedGoogle Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017 [cited 2024 Mar 1]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
   Google Scholar
• Thompson LL, Krasnow NA, Chang MS, et al. Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer. JAMA Dermatol. 2021;157(5):577–582. doi: 10.1001/jamadermatol.2021.0326 PMID: 33760001; PMCID: PMC7992016.
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;392(10145):382–383. doi: 10.1016/S0140-6736(18)31542-3
   PubMedGoogle Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Net. 2019;17(3):255–289. doi: 10.6004/jnccn.2019.0013 PMID: 30865922.
   PubMed Web of Science ®Google Scholar
• Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncology. 2019;24(9):1259–1269. doi: 10.1634/theoncologist.2018-0823 PMID: 30996010; PMCID: PMC6738284.
   Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi: 10.1038/s41572-020-0160-6 PMID: 32382051; PMCID: PMC9728094.
   PubMed Web of Science ®Google Scholar
• Negrini S, Emmi G, Greco M, et al. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9–25. doi: 10.1007/s10238-021-00728-6 PMID: 34100160; PMCID: PMC8863725.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–812. doi: 10.1016/j.jtos.2017.08.003 PMID: 28797892.
   PubMed Web of Science ®Google Scholar
• Baer AN, Walitt B. Update on Sjögren syndrome and other causes of sicca in older adults. Rheum Dis Clin North Am. 2018;44(3):419–436. doi: 10.1016/j.rdc.2018.03.002 PMID: 30001784; PMCID: PMC6245643.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Klimava A, Thorne JE, et al. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea. 2009;28(5):493–497. doi: 10.1097/ICO.0b013e31818d3846 PMID: 19421051; PMCID: PMC2693267.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Maria A, Suárez-Almazor ME, et al. Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol. 2019;37 Suppl 118(3):114–122. PMID: 31464670.
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44. doi: 10.1016/j.ejca.2017.05.032 PMID: 28646772.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (Oxford). 2019;58(Suppl 7):vii40–vii48. doi: 10.1093/rheumatology/kez297 PMID: 31816084; PMCID: PMC6900912.
   PubMedGoogle Scholar
• Harris JA, Huang K, Miloslavsky E, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oral Dis. 2022;28(8):2083–2092. doi: 10.1111/odi.14000 PMID: 34379884.
   PubMed Web of Science ®Google Scholar
• Klein BA, Shazib MA, Villa A, et al. Immune checkpoint inhibitors in cancer therapy: review of orofacial adverse events and role of the oral healthcare provider. Front Oral Health. 2022;3:968157. doi: 10.3389/froh.2022.968157 PMID: 36060116; PMCID: PMC9427772.
   PubMedGoogle Scholar
• Klein BA, Alves FA, de Santana Rodrigues Velho J, et al. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Dis. 2022;28(1):9–22. doi: 10.1111/odi.13964 PMID: 34265157.
   PubMed Web of Science ®Google Scholar
• Baer AN. Diagnosis and classification of Sjögren’s disease - UpToDate. [cited 2023 Sep 6]. Available from: https://www.uptodate.com/contents/diagnosis-and-classification-of-sjogrens-disease
   Google Scholar
• Fox RI, Fox CM, McCoy SS. Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials. Expert Opin Emerg Drugs. 2023;28(2):107–120. doi: 10.1080/14728214.2023.2209720 PMID: 37127914; PMCID: PMC10330372.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Baer AN, Shiboski SC, et al. Natural history and predictors of progression to Sjögren’s syndrome among participants of the Sjögren’s international collaborative clinical alliance registry. Arthritis Care Res (Hoboken). 2018;70(2):284–294. doi: 10.1002/acr.23264 PMID: 28437595; PMCID: PMC5654699.
   PubMed Web of Science ®Google Scholar
• Retamozo S, Acar-Denizli N, Horváth IF, et al. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clin Exp Rheumatol. 2021;Suppl 39(6):166–174. doi: 10.55563/clinexprheumatol/egnd1i PMID: 34919044.
   Web of Science ®Google Scholar
• Brito-Zerón P, Retamozo S, Ramos-Casals M. Sjögren syndrome. Med Clin. 2023;160(4):163–171. doi: 10.1016/j.medcli.2022.10.007 PMID: 36528400.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Vicino A, Michielin O, et al. A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab. J Immunother Cancer. 2018;6(1):110. doi: 10.1186/s40425-018-0429-4 PMID: 30348223; PMCID: PMC6196470.
   PubMedGoogle Scholar
• Le Burel S, Champiat S, Routier E, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis. 2018;77(3):468–470. doi: 10.1136/annrheumdis-2016-210820 PMID: 28242618.
   PubMed Web of Science ®Google Scholar
• Ortiz Brugués A, Sibaud V, Herbault-Barrés B, et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncology. 2020;25(2):e391–e395. doi: 10.1634/theoncologist.2019-0467 PMID: 32043780; PMCID: PMC7011671.
   Google Scholar
• Pringle S, van der Vegt B, Wang X, et al. Lack of conventional acinar cells in parotid salivary gland of patient taking an anti-PD-L1 immune checkpoint inhibitor. Front Oncol. 2020;10:420. doi: 10.3389/fonc.2020.00420 PMID: 32300556; PMCID: PMC7142242.
   PubMed Web of Science ®Google Scholar
• Clark HJ, Fong PCC, Kpl N. Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up. Rheumatology (Oxford). 2021;61(1):e22–e24. PMID: 34508566. doi: 10.1093/rheumatology/keab698
   PubMed Web of Science ®Google Scholar
• Conde-Flores E, Remolina-Bonilla Y, Castro-Alonso F, et al. Sjögren syndrome induced by immune checkpoint inhibitors in a patient with advanced renal cell carcinoma. Oncology (Williston Park). 2021;35(8):486–490. doi: 10.46883/ONC.2021.3508.0486 PMID: 34398593.
   PubMed Web of Science ®Google Scholar
• Simeni Njonnou SR, Aspeslagh S, Ntsama Essomba MJ, et al. Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report. J Med Case Rep. 2022;16(1):456. doi: 10.1186/s13256-022-03663-6 PMID: 36482425; PMCID: PMC9733009.
   PubMedGoogle Scholar
• Caeyman A, Vandekerckhove O, Pat K, et al. Sjögren’s syndrome caused by PD-1 inhibition in a lung cancer patient. Case Rep Oncol. 2023;16(1):1095–1099. doi: 10.1159/000532098 PMID: 37900791; PMCID: PMC10601759.
   PubMedGoogle Scholar
• Ceccarelli F, Natalucci F, Picciariello L, et al. Rheumatic diseases development in patients treated by anti-PD1 immune checkpoint inhibitors: a single-centre descriptive study. Life (Basel). 2023;13(4):877. doi: 10.3390/life13040877 PMID: 37109406; PMCID: PMC10141051.
   PubMed Web of Science ®Google Scholar
• Goules AV, Pringle S, Ramos-Casals M, et al. Pathophysiology of Sjögren’s-like syndrome induced by cancer immunotherapies: similarities and differences with classical Sjögren’s syndrome. Clin Exp Rheumatol. 2022;40(12):2237–2239. doi: 10.55563/clinexprheumatol/v9zras PMID: 36226611.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sicca syndrome following immune checkpoint inhibition. Clin Immunol. 2020;217:108497. doi: 10.1016/j.clim.2020.108497 PMID: 32531346.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Nogueras-Gonzalez GM, Geng Y, et al. Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials. J Immunother Precis Oncol. 2024;7(1):24–40. doi: 10.36401/JIPO-23-14 PMID: 38327757; PMCID: PMC10846637.
   PubMedGoogle Scholar
• Gediz F, Kobak S. Immune checkpoint inhibitors-related rheumatic diseases: what rheumatologist should know? Curr Rheumatol Rev. 2019;15(3):201–208. doi: 10.2174/1573397115666190119094736 PMID: 30659547.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69(11):1751–1763. doi: 10.1002/acr.23177 PMID: 27998041; PMCID: PMC5478477.
   PubMed Web of Science ®Google Scholar
• Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immun. 2018;67(2):175–182. doi: 10.1007/s00262-017-2069-9 PMID: 29018908.
   PubMed Web of Science ®Google Scholar
• Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–338. doi: 10.1136/annrheumdis-2019-216109 PMID: 31540935; PMCID: PMC7031780.
   PubMed Web of Science ®Google Scholar
• Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018;138(7):743–745. doi: 10.1161/CIRCULATIONAHA.118.035898 PMID: 30359135.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19(8):102586. PMID: 32535094. doi: 10.1016/j.autrev.2020.102586
   PubMed Web of Science ®Google Scholar
• Raschi E, Antonazzo IC, Poluzzi E, et al. Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Ann Rheum Dis. 2021;80(7):e120. PMID: 31189551. doi: 10.1136/annrheumdis-2019-215819
   PubMed Web of Science ®Google Scholar
• Roberts J, Ennis D, Hudson M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19(8):102595. doi: 10.1016/j.autrev.2020.102595 PMID: 32535092.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, et al. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. PMID: 29320654. doi: 10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. PMID: 35082367; PMCID: PMC8790946. doi: 10.1038/s41571-022-00600-w
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–2816. doi: 10.1002/art.22070 PMID: 16947384.
   PubMed Web of Science ®Google Scholar
• Borst J, Busselaar J, Bosma DMT, et al. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021;51(8):1911–1920. PMID: 34106465; PMCID: PMC8453912. doi: 10.1002/eji.202048994
   PubMed Web of Science ®Google Scholar
• Reid P, Cappelli LC. Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022;36(4):101805. PMID: 36539321; PMCID: PMC10198805. doi: 10.1016/j.berh.2022.101805
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3(1):39. doi: 10.1186/s40425-015-0081-1 PMID: 26380086; PMCID: PMC4570556.
   PubMedGoogle Scholar
• Johnson DH, Hailemichael Y, Foo WC, et al. Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. J Clin Oncol. 2019;37(15):2616–2616. doi: 10.1200/JCO.2019.37.15_suppl.2616
   Web of Science ®Google Scholar
• Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747–1750. doi: 10.1136/annrheumdis-2017-211216 PMID: 28600350.
   PubMed Web of Science ®Google Scholar
• Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–136. doi: 10.1016/j.ejca.2017.05.041 PMID: 28666240.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9. PMID: 20957980; PMCID: PMC2964017.
   PubMedGoogle Scholar
• Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14. doi: 10.1016/j.ejca.2018.11.009 PMID: 30529903.
   PubMed Web of Science ®Google Scholar
• Quandt Z, Kim S, Villanueva-Meyer J, et al. Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis. J Endocr Soc. 2023;7(4):bvad012. PMID: 36860908; PMCID: PMC9969737. doi: 10.1210/jendso/bvad012
   PubMed Web of Science ®Google Scholar
• Wölffer M, Battke F, Schulze M, et al. Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma. Cancers (Basel). 2022;14(2):302. PMID: 35053465; PMCID: PMC8773840. doi: 10.3390/cancers14020302
   PubMed Web of Science ®Google Scholar
• Abed A, Law N, Calapre L, et al. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. Eur J Cancer. 2022;172:98–106. PMID: 35759816. doi: 10.1016/j.ejca.2022.05.021
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391. doi: 10.1038/ncomms10391 PMID: 26837003; PMCID: PMC4740747.
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–1379. PMID: 28368458. doi: 10.1093/annonc/mdx108
   PubMed Web of Science ®Google Scholar
• Hu M, Lin X, Sun T, et al. Gut microbiome for predicting immune checkpoint blockade-associated adverse events. Genome Med. 2024;16(1):16. doi: 10.1186/s13073-024-01285-9 PMID: 38243343; PMCID: PMC10799412.
   PubMed Web of Science ®Google Scholar
• Ghanbar MI, Suresh K. Pulmonary toxicity of immune checkpoint immunotherapy. J Clin Invest. 2024;134(2):e170503. PMID: 38226621; PMCID: PMC10786690. doi: 10.1172/JCI170503
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jia D, Sun Y, et al. Microbiota: a key factor affecting and regulating the efficacy of immunotherapy. Clin Transl Med. 2023;13(12):e1508. doi: 10.1002/ctm2.1508 PMID: 38082435; PMCID: PMC10713876.
   PubMed Web of Science ®Google Scholar
• Santangelo BE, Apgar M, Colorado ASB, et al. Integrating biological knowledge for mechanistic inference in the host-associated microbiome. Front Microbiol. 2024;15:1351678. doi: 10.3389/fmicb.2024.1351678 PMID: 38638909; PMCID: PMC11024261.
   PubMed Web of Science ®Google Scholar
• McCoy SS, Sampene E, Baer AN. Association of Sjögren’s syndrome with reduced lifetime sex hormone exposure: a case-control study. Arthritis Care Res (Hoboken). 2020;72(9):1315–1322. PMID: 31233285; PMCID: PMC6928446. doi: 10.1002/acr.24014
   PubMed Web of Science ®Google Scholar
• Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjögren’s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33–45. PMID: 30774485; PMCID: PMC6357904. doi: 10.2147/OARRR.S167783
   PubMed Web of Science ®Google Scholar
• Parisis D, Chivasso C, Perret J, et al. Current state of knowledge on primary Sjögren’s syndrome, an autoimmune exocrinopathy. J Clin Med. 2020;9(7):2299. doi: 10.3390/jcm9072299 PMID: 32698400; PMCID: PMC7408693.
   PubMed Web of Science ®Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34(4):400–407. PMID: 19889514. doi: 10.1016/j.jaut.2009.10.004
   PubMed Web of Science ®Google Scholar
• Mielle J, Tison A, Cornec D, et al. B cells in Sjögren’s syndrome: from pathophysiology to therapeutic target. Rheumatology (Oxford). 2021;60(6):2545–2560. doi: 10.1093/rheumatology/key332 PMID: 30770916.
   PubMed Web of Science ®Google Scholar
• Chivasso C, Sarrand J, Perret J, et al. The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjögren’s syndrome. Int J Mol Sci. 2021;22(2):658. PMID: 33440862; PMCID: PMC7826728. doi: 10.3390/ijms22020658
   PubMed Web of Science ®Google Scholar
• Yao Y, Ma JF, Chang C, et al. Immunobiology of T cells in Sjögren’s syndrome. Clin Rev Allergy Immunol. 2021;60(1):111–131. doi: 10.1007/s12016-020-08793-7 PMID: 32390096.
   PubMed Web of Science ®Google Scholar
• Pringle S, Wang X, Vissink A, et al. Checkpoint inhibition-induced sicca: a type II interferonopathy? Clin Exp Rheumatol. 2020;38(4):253–260. PMID: 33025881.
   PubMed Web of Science ®Google Scholar
• Kwon J, Surenkhuu B, Raju I, et al. Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease. Ocul Surf. 2020;18(1):80–97. doi: 10.1016/j.jtos.2019.10.004 PMID: 31606460.
   PubMed Web of Science ®Google Scholar
• Park RB, Jain S, Han H, et al. Ocular surface disease associated with immune checkpoint inhibitor therapy. Ocul Surf. 2021;20:115–129. PMID: 33610743. doi: 10.1016/j.jtos.2021.02.004
   PubMed Web of Science ®Google Scholar
• Richter MD, Crowson C, Kottschade LA, et al. Rheumatic syndromes associated with immune checkpoint Inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468–475. PMID: 30281202. doi: 10.1002/art.40745
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712–720. doi: 10.1158/1078-0432.CCR-14-2468 PMID: 25524312; PMCID: PMC4620684.
   PubMed Web of Science ®Google Scholar
• Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17(4):896–906. doi: 10.1158/1078-0432.CCR-10-2463 PMID: 21106722; PMCID: PMC3041838.
   PubMed Web of Science ®Google Scholar
• Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021;105(9):1263–1271. PMID: 32830124. doi: 10.1136/bjophthalmol-2020-316970
   PubMed Web of Science ®Google Scholar
• Mazharuddin AA, Whyte AT, Gombos DS, et al. Highlights on ocular toxicity of immune checkpoint inhibitors at a US Tertiary Cancer Center. J Immunother Precis Oncol. 2022;5(4):98–104. doi: 10.36401/JIPO-22-14 PMID: 36483585; PMCID: PMC9714419.
   PubMedGoogle Scholar
• Yildirim OA, Poyraz K, Erdur E, et al. Nivolumab-related dry mouth and dry eye: cross-sectional study. Cancer Invest. 2021;39(10):797–807. PMID: 34415812. doi: 10.1080/07357907.2021.1971241
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7 PMID: 26712084.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–1437. PMID: 25452452; PMCID: PMC4806782. doi: 10.1200/JCO.2014.59.0703
   PubMed Web of Science ®Google Scholar
• Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4(2):e000714. PMID: 30167328; PMCID: PMC6109812. doi: 10.1136/rmdopen-2018-000714
   PubMed Web of Science ®Google Scholar
• Narváez J, Castro-Bohorquez FJ, Vilaseca-Momplet J. Sjögren’s-like syndrome following intravesical bacillus Calmette-Guérin immunotherapy. Am J Med. 2003;115(5):418–420. PMID: 14553888. doi: 10.1016/s0002-9343(03)00398-x
   PubMed Web of Science ®Google Scholar
• Isshiki I, Okamoto S, Kakimoto T, et al. Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. Int J Hematol. 2006;84(4):354–358. doi: 10.1532/IJH97.06029 PMID: 17118763.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412. doi: 10.1136/rmdopen-2016-000412 PMID: 28405474; PMCID: PMC5372131.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50. doi: 10.1136/annrheumdis-2016-209595 PMID: 27307501; PMCID: PMC5333990.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–376. doi: 10.1093/annonc/mdw443 PMID: 27687304.
   PubMed Web of Science ®Google Scholar
• Teyssonneau D, Cousin S, Italiano A. Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Ann Oncol. 2017;28(12):3108. PMID: 29045656. doi: 10.1093/annonc/mdx531
   PubMed Web of Science ®Google Scholar
• Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–29. PMID: 29331748. doi: 10.1016/j.ejca.2017.12.008
   PubMed Web of Science ®Google Scholar
• Lomax AJ, Lim J, Cheng R, et al. Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management. J Skin Cancer. 2018;2018:1–13. PMID: 29610684; PMCID: PMC5828308. doi: 10.1155/2018/9602540
   Google Scholar
• Narváez J, Juarez-López P, LLuch J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev. 2018;17(10):1040–1045. PMID: 30103042. doi: 10.1016/j.autrev.2018.05.002
   PubMed Web of Science ®Google Scholar
• Richter MD, Pinkston O, Kottschade LA, et al. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol. 2018;70(3):356–360. PMID: 29363290. doi: 10.1002/art.40397
   PubMed Web of Science ®Google Scholar
• Takahashi S, Chieko X, Sakai T, et al. Nivolumab-induced sialadenitis. Respirol Case Rep. 2018;6(5):e00322. PMID: 29686875; PMCID: PMC5899999. doi: 10.1002/rcr2.322
   PubMedGoogle Scholar
• Higashi T, Miyamoto H, Yoshida R, et al. Sjögren’s syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer. Intern Med. 2020;59(20):2499–2504. doi: 10.2169/internalmedicine.4701-20 PMID: 32581160; PMCID: PMC7662059.
   PubMed Web of Science ®Google Scholar
• Brown LJ, Weppler A, Bhave P, et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021;9(5):e002121. doi: 10.1136/jitc-2020-002121 PMID: 33963010; PMCID: PMC8108669.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mazón I, Sánchez-Bilbao L, Martín-Varillas JL, et al. Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clin Exp Rheumatol. 2021;39(3):612–620. doi: 10.55563/clinexprheumatol/o5nvgv PMID: 32896258.
   PubMed Web of Science ®Google Scholar
• Katsura K, Funayama S, Ito K, et al. Radiological imaging features of the salivary glands in xerostomia induced by an immune checkpoint inhibitor. Oral Radiol. 2021;37(3):531–536. doi: 10.1007/s11282-020-00480-9 PMID: 32893314; PMCID: PMC8214578.
   PubMed Web of Science ®Google Scholar
• Tostes FT, Fernandes I, Segatelli V, et al. Response to pembrolizumab in advanced anal squamous cell carcinoma with high TMB and PD-L1 and PD-L2 amplification. Clin Colorectal Cancer. 2021;20(4):350–353. PMID: 34154923. doi: 10.1016/j.clcc.2021.05.008
   PubMed Web of Science ®Google Scholar
• Chaudot F, Sève P, Rousseau A, et al. Ocular inflammation induced by immune checkpoint inhibitors. J Clin Med. 2022;11(17):4993. PMID: 36078923; PMCID: PMC9456546. doi: 10.3390/jcm11174993
   PubMed Web of Science ®Google Scholar
• Song K, Dong H, Jiang S, et al. Case report: a rare case of sintilimab-induced gastric stenosis and literature review. Front Oncol. 2023;13:1091459. doi: 10.3389/fonc.2023.1091459 PMID: 36761970; PMCID: PMC9906806.
   PubMed Web of Science ®Google Scholar
• Liu H, Li Y, Li J, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023;14:1199031. doi: 10.3389/fphar.2023.1199031 PMID: 37881181; PMCID: PMC10595016.
   PubMed Web of Science ®Google Scholar
• Sheng L, Zhang Y, Song Q, et al. Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol. 2023;14:1298815. doi: 10.3389/fimmu.2023.1298815 PMID: 38173731; PMCID: PMC10762793.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. doi: 10.3390/cancers12030738 PMID: 32245016; PMCID: PMC7140028.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45. PMID: 27785888; PMCID: PMC5650478. doi: 10.1002/art.39859
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–558. doi: 10.1136/ard.61.6.554 PMID: 12006334; PMCID: PMC1754137.
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–1109. PMID: 19561361; PMCID: PMC2937022. doi: 10.1136/ard.2009.110619
   PubMed Web of Science ®Google Scholar
• Le Goff M, Cornec D, Jousse-Joulin S, et al. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome. Arthritis Res Ther. 2017;19(1):269. PMID: 29208023; PMCID: PMC5717850. doi: 10.1186/s13075-017-1475-x
   PubMed Web of Science ®Google Scholar
• Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis. 2019;78(7):967–973. doi: 10.1136/annrheumdis-2019-215024 PMID: 31036626.
   PubMed Web of Science ®Google Scholar
• Trevisani VFM, Pasoto SG, Fernandes MLMS, et al. Recommendations from the Brazilian Society of Rheumatology for the diagnosis of Sjögren’s syndrome (Part I): glandular manifestations (systematic review). Adv Rheumatol. 2019;59(1):58. PMID: 31852541. doi: 10.1186/s42358-019-0102-8
   PubMedGoogle Scholar
• Laver NMV. Ocular cytology: diagnostic features and ongoing practices. Cancer Cytopathol. 2021;129(6):419–431. PMID: 33136340. doi: 10.1002/cncy.22384
   PubMed Web of Science ®Google Scholar
• Wu KY, Serhan O, Faucher A, et al. Advances in Sjögren’s syndrome dry eye diagnostics: biomarkers and biomolecules beyond clinical symptoms. Biomolecules. 2024;14(1):80. doi: 10.3390/biom14010080 PMID: 38254680; PMCID: PMC10812982.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis. 2017;76(6):1042–1050. PMID: 27899373. doi: 10.1136/annrheumdis-2016-209952
   PubMed Web of Science ®Google Scholar
• Ibn Yacoub Y, Rostom S, Laatiris A, et al. Primary Sjögren’s syndrome in Moroccan patients: characteristics, fatigue and quality of life. Rheumatol Int. 2012;32(9):2637–2643. doi: 10.1007/s00296-011-2009-5 PMID: 21786120.
   PubMed Web of Science ®Google Scholar
• Warner BM, Baer AN. Sicca syndromes. In: Suarez-Almazor M Calabrese L, editors. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. A Handbook for Diagnosis and Management. Springer; 2021. p. 109–142. doi: 10.1007/978-3-030-56824-5
   Google Scholar
• Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–889. doi: 10.1136/annrheumdis-2018-214436 PMID: 30862649; PMCID: PMC6585284.
   PubMed Web of Science ®Google Scholar
• Routsias JG, Tzioufas AG. Sjögren’s syndrome–study of autoantigens and autoantibodies. Clin Rev Allergy Immunol. 2007;32(3):238–251. PMID: 17992591. doi: 10.1007/s12016-007-8003-8
   PubMed Web of Science ®Google Scholar
• Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren’s syndrome. Rheum Dis Clin North Am. 2016;42(3):419–434. doi: 10.1016/j.rdc.2016.03.002 PMID: 27431345; PMCID: PMC4955792.
   PubMed Web of Science ®Google Scholar
• Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009;8(7):632–637. PMID: 19393201. doi: 10.1016/j.autrev.2009.02.010
   PubMed Web of Science ®Google Scholar
• Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017;37(8):1323–1333. PMID: 28417151. doi: 10.1007/s00296-017-3718-1
   PubMed Web of Science ®Google Scholar
• Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity. 2005;38(1):55–63. PMID: 15804706. doi: 10.1080/08916930400022954
   PubMed Web of Science ®Google Scholar
• Baer AN, McAdams DeMarco M, Shiboski SC, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis. 2015;74(8):1557–1561. doi: 10.1136/annrheumdis-2014-206683 PMID: 25735642; PMCID: PMC6697481.
   PubMed Web of Science ®Google Scholar
• Acar-Denizli N, Horváth IF, Mandl T, et al. Systemic phenotype related to primary Sjögren’s syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clin Exp Rheumatol. 2020;38 Suppl 126(4):85–94. PMID: 33095152.
   PubMed Web of Science ®Google Scholar
• Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009;68(6):828–835. doi: 10.1136/ard.2008.088054 PMID: 18625627; PMCID: PMC3558032.
   PubMed Web of Science ®Google Scholar
• Jonsson R, Theander E, Sjöström B, et al. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA. 2013;310(17):1854–1855. PMID: 24193084. doi: 10.1001/jama.2013.278448
   PubMed Web of Science ®Google Scholar
• Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 2015;67(9):2427–2436. PMID: 26109563. doi: 10.1002/art.39214
   PubMed Web of Science ®Google Scholar
• Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun. 2012;39(1–2):15–26. PMID: 22575069. doi: 10.1016/j.jaut.2012.03.001
   PubMed Web of Science ®Google Scholar
• Malladi AS, Sack KE, Shiboski SC, et al. Primary Sjögren’s syndrome as a systemic disease: a study of participants enrolled in an international Sjögren’s syndrome registry. Arthritis Care Res (Hoboken). 2012;64(6):911–918. doi: 10.1002/acr.21610 PMID: 22238244; PMCID: PMC3595164.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol. 2018;36 Suppl 112(3):102–112. PMID: 30156539.
   PubMed Web of Science ®Google Scholar
• Robbins A, Hentzien M, Toquet S, et al. Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 antibody detection in autoimmune diseases. Front Immunol. 2019;10:444. PMID: 30915082; PMCID: PMC6423153. doi: 10.3389/fimmu.2019.00444
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Ferré EMN, Chaturvedi A, et al. Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res. 2019;98(7):772–778. PMID: 31095438; PMCID: PMC6589895. doi: 10.1177/0022034519850564
   PubMed Web of Science ®Google Scholar
• Tang H, Geng R, Xu X, et al. Safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting autoantibodies. Front Immunol. 2022;13:893179. doi: 10.3389/fimmu.2022.893179 PMID: 35651612; PMCID: PMC9148956.
   PubMed Web of Science ®Google Scholar
• Chan EKL, von Mühlen CA, Fritzler MJ, et al. The International Consensus on ANA Patterns (ICAP) in 2021-the 6th Workshop and current perspectives. J Appl Lab Med. 2022;7(1):322–330. doi: 10.1093/jalm/jfab140 PMID: 34996073.
   PubMedGoogle Scholar
• Langguth DM, Morris S, Clifford L, et al. Specific testing for “isolated” anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. J Clin Pathol. 2007;60(6):670–673. doi: 10.1136/jcp.2006.040360 PMID: 17557869; PMCID: PMC1955071.
   PubMed Web of Science ®Google Scholar
• Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–383. doi: 10.1001/jamaoncol.2018.5860 PMID: 30589930; PMCID: PMC6439838.
   PubMed Web of Science ®Google Scholar
• Zhang D, Shi Y, Liu X, et al. Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study. Transl Lung Cancer Res. 2022;11(7):1420–1433. doi: 10.21037/tlcr-22-464 PMID: 35958331; PMCID: PMC9359963.
   PubMed Web of Science ®Google Scholar
• Sakakida T, Ishikawa T, Chihara Y, et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol. 2020;22(6):919–927. doi: 10.1007/s12094-019-02214-8 PMID: 31576495.
   PubMed Web of Science ®Google Scholar
• Nocturne G, Virone A, Ng WF, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68(4):977–985. doi: 10.1002/art.39518 PMID: 26606524.
   PubMed Web of Science ®Google Scholar
• Zhang K, Kong X, Li Y, et al. PD-1/PD-L1 Inhibitors in patients with preexisting autoimmune diseases. Front Pharmacol. 2022;13:854967. doi: 10.3389/fphar.2022.854967 PMID: 35370736; PMCID: PMC8971753.
   PubMed Web of Science ®Google Scholar
• Elad S, Yarom N, Zadik Y. Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer. Cancers (Basel). 2023;15(19):4781. doi: 10.3390/cancers15194781 PMID: 37835475; PMCID: PMC10571987.
   PubMed Web of Science ®Google Scholar
• Bustillos H, Indorf A, Alwan L, et al. Xerostomia: an immunotherapy-related adverse effect in cancer patients. Support Care Cancer. 2022;30(2):1681–1687. doi: 10.1007/s00520-021-06535-9 PMID: 34562169.
   PubMed Web of Science ®Google Scholar
• Segawa T, Motoshima T, Yatsuda J, et al. Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma. IJU Case Rep. 2023;6(2):147–149. doi: 10.1002/iju5.12573 PMID: 36874997; PMCID: PMC9978085.
   PubMedGoogle Scholar
• Steven NM, Fisher BA. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective. Rheumatology (Oxford). 2019;58(Suppl 7):vii29–vii39. doi: 10.1093/rheumatology/kez536 PMID: 31816079; PMCID: PMC6900910.
   PubMedGoogle Scholar
• Vigarios E, Sibaud V. Oral mucosal toxicities induced by immune checkpoint inhibitors: clinical features and algorithm management. Ann Dermatol Venereol. 2023;150(2):83–88. doi: 10.1016/j.annder.2022.11.012 PMID: 36935341.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3–18. doi: 10.1136/annrheumdis-2019-216114 PMID: 31672775.
   PubMed Web of Science ®Google Scholar
• Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859. doi: 10.1080/09273948.2019.1583347 PMID: 31013173; PMCID: PMC8130843.
   PubMed Web of Science ®Google Scholar
• Chen K, Ibañez Bruron MC, Mondaca S, et al. Quantitative ocular surface changes in patients undergoing immune checkpoint inhibitor therapy. Ocul Immunol Inflamm. 2023 Sep;18:1–4. doi: 10.1080/09273948.2023.2252892 PMID: 37722802.
   Google Scholar
• Boucher R, Haigh O, Barreau E, et al. Ocular surface toxicities associated with modern anticancer therapies. Surv Ophthalmol. 2024;69(2):198–210. doi: 10.1016/j.survophthal.2023.10.002 PMID: 37806566.
   PubMedGoogle Scholar
• Yura Y, Hamada M. Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases. Cancers (Basel). 2022;14(3):792. doi: 10.3390/cancers14030792 PMID: 35159059; PMCID: PMC8834130.
   PubMed Web of Science ®Google Scholar
• Tanasiewicz M, Hildebrandt T, Obersztyn I. Xerostomia of various etiologies: a review of the literature. Adv Clin Exp Med. 2016;25(1):199–206. doi: 10.17219/acem/29375 PMID: 26935515.
   PubMed Web of Science ®Google Scholar